National rollout of a medication safety dashboard to improve testing for latent infections among biologic and targeted synthetic disease‐modifying agent users within the Veterans Health Administration.

Objective Data Sources and Study Setting Study Design Data Collection Methods Principal Findings Conclusions To develop, deploy, and evaluate a national, electronic health record (EHR)‐based dashboard to support safe prescribing of biologic and targeted synthetic disease‐modifying agents (b/tsDMARDs) in the United States Veterans Affairs Healthcare System (VA).We extracted and displayed hepatitis B (HBV), hepatitis C (HCV), and tuberculosis (TB) screening data from the EHR for users of b/tsDMARDs using PowerBI (Microsoft) and deployed the dashboard to VA facilities across the United States in 2022; we observed facilities for 44 weeks post‐deployment.We examined the association between dashboard engagement by healthcare personnel and the percentage of patients with all screenings complete (HBV, HCV, and TB) at the facility level using an interrupted time series. Based on frequency of sessions, facilities were grouped into high‐ and low/none‐engagement categories. We modeled changes in complete screening pre‐ and post‐deployment of the dashboard.All VA facilities were eligible for inclusion; excluded facilities participated in design of the dashboard or had <20 patients receiving b/tsDMARDs. Session counts from facility personnel were captured using PowerBI audit log data. Outcomes were assessed weekly based on EHR data extracted via the dashboard itself.Totally 117 facilities (serving a total of 41,224 Veterans prescribed b/tsDMARDs) were included. Before dashboard deployment, across all facilities, 61.5% of patients had all screenings complete, which improved to 66.3% over the course of the study period. The largest improvement (15 percentage points, 60.3%–75.3%) occurred among facilities with high engagement (post‐intervention difference in outcome between high and low/none‐engagement groups was 0.17 percentage points (pp) per week, 95% confidence interval (0.04 pp, 0.30 pp); p = 0.01).We observed significant improvements in screening for latent infections among facilities with high engagement with the dashboard, compared with those with fewer sessions. [ABSTRACT FROM AUTHOR]